CD44 and prostate cancer: OPN, a ligand for CD44, intergrins, and other cell surface receptors, is implicated in tumor progression [35], and has been shown recently to correlate with response to chemotherapy in metastatic CRPC [36], and in a meta-analysis was significantly associated with survival in several cancers, including prostate cancer [37].